AOD-9604 5mg Review

AOD-9604 occupies a specific and well-defined corner of the growth-hormone peptide landscape. Unlike the full 191-amino-acid sequence of human growth hormone (hGH), this fragment spans only residues 176-191 of the hGH C-terminus, preserving what early structural biology research identified as the lipid-mobilizing domain of the parent molecule while discarding the growth-promoting and insulin-sensitizing portions. The research rationale is elegant: if adipose tissue mobilization can be decoupled from the proliferative and diabetogenic effects of intact hGH, the resulting molecule might have a cleaner research safety profile for metabolic studies.

The compound has an unusually documented regulatory history for a research peptide. Metabolic Pharmaceuticals Ltd (Melbourne, Australia) advanced it through Phase I through Phase IIb human clinical trials under the brand name Obesity Control (OC). That program ultimately did not achieve the efficacy threshold required for regulatory approval as a standalone obesity drug, but it generated a body of pharmacokinetic, tolerability, and dose-finding data that most research peptides simply do not have. 1 Researchers working with AOD-9604 therefore benefit from unusually robust foundational data, even as many mechanistic questions remain unresolved.

This review covers the published research literature, pharmacokinetics, purity verification expectations, and a full comparison against related compounds in the same functional category. The 5 mg vial format offered through Apollo Peptide Sciences under the catalog identifier aod-9604-peptide-2 is evaluated below.

Editor's Verdict

AOD-9604's value as a research tool lies in its structural specificity. Because it retains the beta-3 adrenergic receptor-linked signaling of the parent hGH molecule without activating IGF-1 production or the hGH receptor's growth-promoting cascade to a measurable degree, it allows researchers to probe fat-cell biology in a pharmacologically selective way. 2 The literature documents effects on adipocyte lipolysis, lipogenesis inhibition, and preliminary data on cartilage repair and bone metabolism that are covered in depth below.

Specifications

The 5 mg lyophilized vial is the most common format for AOD-9604 in the research supply market. Lyophilization preserves peptide integrity during shipping and allows a stated shelf life of 24-36 months when stored correctly at -20°C. Once reconstituted, the solution is considerably more labile and should be aliquoted and stored at -80°C if the full vial will not be used within four weeks.

What It Is, Chemistry, Origin, and Sequence Detail

Origins in hGH Structural Biology

Human growth hormone is a 191-amino-acid single-chain polypeptide with two disulfide bridges. By the early 1990s, structural biologists had mapped several functionally distinct regions within the full molecule: the receptor-binding domains responsible for somatic growth, the region modulating insulin sensitivity, and what was then hypothesised to be a lipid-mobilizing "lipolytic domain" near the C-terminus. 3

The Monash University group led by Dr. Frank Ng performed the foundational isolation work on this C-terminal region. Systematic truncation and activity assays confirmed that residues 176-191 of hGH retained the capacity to stimulate lipolysis in isolated adipocytes and to reduce adipogenesis without producing the hyperglycaemic effects observed with the intact hormone. 4 The earliest publications describing this fragment appeared in the late 1990s, and Metabolic Pharmaceuticals Ltd subsequently licensed and developed it as a potential anti-obesity compound.

The naming convention "AOD" is an abbreviation for "Anti-Obesity Drug," reflecting the original commercial intent. The number "9604" was an internal development identifier rather than a sequence position reference.

Sequence Architecture and the Critical Disulfide Bridge

The 16-amino-acid sequence YLRIVQCRSVEGSCGF contains two cysteine residues at positions 7 and 14 within the fragment (corresponding to Cys182 and Cys189 of the parent hGH molecule). These cysteines form a disulfide bridge that creates a loop structure essential for biological activity. Linear analogs in which this bridge is reduced or absent show substantially diminished lipolytic activity in cell-free and cell-based assays, confirming that the tertiary structure imposed by the disulfide bond is pharmacodynamically required. 5

The N-terminal tyrosine residue in AOD-9604 is not present in native hGH at this position; it was added during early research to enable radioiodination for receptor-binding autoradiography and pharmacokinetic tracking with ¹²⁵I labeling. The tyrosine was retained in subsequent development because it appeared to stabilize the molecule and did not significantly alter the lipid-related activity profile in rodent models. 6

From a synthetic chemistry standpoint, producing a correctly folded, disulfide-bonded 16-mer with high purity is a non-trivial challenge for peptide manufacturers. Incorrect disulfide pairing (scrambled cysteines) produces an inactive or reduced-activity isomer that may co-elute with the correct form on low-resolution HPLC columns. This is a primary reason why high-resolution mass spectrometry confirmation of the correct molecular ion, rather than HPLC purity alone, is the preferred quality benchmark for AOD-9604 research vials.

Physical and Chemical Properties

AOD-9604 has a molecular weight of approximately 1815.1 Da and a molecular formula of C₇₈H₁₂₃N₂₃O₂₃S₂. The peptide carries a net charge that is moderately acidic at physiological pH, which influences its solubility behavior. Solubility in bacteriostatic water is reported at greater than 1 mg/mL, making standard reconstitution protocols straightforward. The compound is sensitive to oxidative conditions in solution, particularly at elevated temperatures, and the intact disulfide bridge can undergo thiol-disulfide exchange under certain buffer conditions. Researchers should avoid DMSO-based diluents, which can reduce disulfide bonds. Sterile bacteriostatic water at neutral pH, as recommended in the peptide reconstitution guide, is the standard laboratory approach.

Mechanism of Action

Beta-3 Adrenergic Receptor Involvement

The primary lipolytic mechanism of AOD-9604 appears to involve signaling through beta-3 adrenergic receptors (ADRB3) expressed on adipocytes. Beta-3 receptors are G-protein-coupled receptors (GPCRs) linked to Gs proteins; their activation elevates intracellular cyclic AMP (cAMP), activates protein kinase A (PKA), and ultimately promotes phosphorylation and activation of hormone-sensitive lipase (HSL), the enzyme responsible for triglyceride hydrolysis within fat cells. 2

Preclinical work in obese Zucker rats demonstrated that AOD-9604 increased adipocyte lipolysis in a dose-dependent manner and that this effect was blocked by selective beta-3 antagonists, implicating ADRB3 as the primary transduction mechanism. 7 The specificity for beta-3 rather than beta-1 or beta-2 adrenergic receptors is particularly significant from a research perspective because ADRB3 is predominantly expressed in adipose tissue and has minimal representation in cardiac tissue, theoretically reducing the cardiovascular stimulant liability associated with non-selective adrenergic agonism.

The exact binding site on ADRB3 for AOD-9604 has not been resolved to atomic resolution by crystallography or cryo-EM as of the time of writing, which is one of the open research questions discussed later in this article. Competitive radioligand displacement assays have confirmed that AOD-9604 interacts with ADRB3, but the precise binding pocket geometry remains to be fully characterized.

Inhibition of Lipogenesis

Beyond stimulating lipolysis, AOD-9604 has been shown to inhibit lipogenesis through a partially independent pathway. In studies using isolated rat adipocytes, the fragment reduced the incorporation of radiolabeled acetate into triglycerides, an established measure of de novo lipid synthesis. 8 This dual action, simultaneously promoting breakdown of stored fat and inhibiting new fat synthesis, may explain why the magnitude of fat-mass reduction observed in animal studies exceeded what would be predicted from lipolysis stimulation alone.

The transcriptional mechanism underlying lipogenesis inhibition may involve downregulation of sterol regulatory element-binding protein 1c (SREBP-1c), a master transcription factor that governs the expression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). This pathway has been inferred from gene expression studies in rodent adipose tissue but has not been confirmed through chromatin immunoprecipitation or direct promoter-binding assays in the AOD-9604 context specifically, so it remains a mechanistic hypothesis rather than an established fact.

Absence of IGF-1 Stimulation and Growth Receptor Activity

One of the most important mechanistic features distinguishing AOD-9604 from full-length hGH is the absence of measurable IGF-1 stimulation. Full-length hGH binds the GH receptor and triggers JAK2/STAT5b phosphorylation in the liver, driving hepatic IGF-1 production. IGF-1 in turn mediates most of the anabolic and proliferative effects of GH. 3

Multiple in-vivo studies confirm that AOD-9604 administration does not produce detectable elevations in serum IGF-1 in rodents. Importantly, the Phase I human clinical trials also found no IGF-1 elevation following oral or parenteral AOD-9604 administration across dose ranges from 0.25 mg to 9 mg per day, distinguishing it pharmacodynamically from rhGH administration. 1 From a research design standpoint, this selectivity makes AOD-9604 a useful probe for isolating the fat-metabolism arm of GH pharmacology from its growth-promoting arm.

Effects on Adipocyte Differentiation

A third mechanistic domain concerns adipogenesis itself. In vitro work using 3T3-L1 preadipocyte cell lines demonstrated that AOD-9604 treatment reduced differentiation of preadipocytes into mature adipocytes, assessed by Oil Red O staining of lipid droplet accumulation and expression of the differentiation marker PPAR-gamma. 9 This anti-adipogenic effect operates partly independently of the lipolysis pathway, suggesting AOD-9604 acts at multiple stages of adipocyte biology: inhibiting the genesis of new fat cells while simultaneously promoting the mobilization of triglycerides in existing ones.

Bone and Cartilage Research

More recently, a line of investigation distinct from the original obesity focus has emerged around AOD-9604's potential effects on bone and cartilage metabolism. The peptide has been studied as a component in combination formulations for osteoarthritis, both alone and in combination with sodium hyaluronate. 10 In vitro chondrocyte studies and rodent joint injection models have reported increased proteoglycan synthesis and reduced degradation marker expression following AOD-9604 treatment. The mechanistic basis for these effects is not linked to the ADRB3 lipolysis pathway; instead, preliminary evidence points toward interaction with the TGF-beta signaling axis in chondrocytes. This is an area of active but early-stage research and should be interpreted with appropriate caution.

Tissue Distribution of Receptors and Predicted Activity Sites

ADRB3 expression in humans is highest in adipose tissue (both white and brown), with lower expression in the gastrointestinal tract, gallbladder, and urinary bladder. The adipose-enriched distribution of the receptor is consistent with the tissue-specific activity profile observed for AOD-9604 in animal studies, where fat-mass changes occur without corresponding changes in lean body mass or organ weights. 2 This receptor-distribution profile is distinct from, for example, GLP-1 receptor agonists, which achieve systemic metabolic effects through receptors distributed across the gut, pancreas, and central nervous system.

What the Research Says

Study 1, Ng et al., Preclinical Characterization of the Lipolytic Domain

The foundational preclinical work establishing AOD-9604 as a pharmacologically active compound comes from the laboratory that originally isolated the fragment. Ng and colleagues characterized the lipolytic activity of hGH C-terminal fragments across a series of in vitro and ex vivo assays. Using isolated rat epididymal adipocytes, they measured glycerol release as a marker of triglyceride hydrolysis following peptide treatment. The AOD-9604 sequence produced concentration-dependent increases in glycerol release, with an EC50 in the low nanomolar range in the in vitro system. 8

The study design used radiolabeled acetate incorporation assays alongside the glycerol release measurements to simultaneously assess lipogenesis, enabling direct comparison of lipogenesis inhibition and lipolysis stimulation at the same peptide concentrations. The finding that both effects occurred in overlapping concentration ranges was taken as evidence of a unified mechanism rather than two independent pharmacological actions at separate receptor sites.

Critically, the authors also compared the AOD-9604 response to full-length hGH and to two truncated analogs with the disulfide bridge disrupted. The intact disulfide form (AOD-9604 as standardly supplied) showed the highest lipolytic potency, with the linearized (reduced) form showing approximately 30% of the activity and a scrambled-disulfide form showing less than 10% activity. This established a clear structure-activity relationship (SAR) that informs quality standards for research vials: the disulfide bond status is a direct predictor of biological activity. 5

The limitation of this early work is that it was conducted entirely in isolated adipocyte preparations, which do not fully recapitulate the complexity of adipose tissue in situ, including paracrine signaling, sympathetic innervation, and interactions with infiltrating immune cells. The in vitro EC50 data therefore cannot be extrapolated linearly to in vivo dosing requirements.

Study 2, Obese Rodent In Vivo Work on Body Composition

Building on the in vitro characterization, researchers conducted a series of chronic dosing studies in diet-induced obese (DIO) mice and in genetically obese (ob/ob) mice to establish whether the in vitro lipolytic effects translated to in vivo fat-mass reductions. In the DIO model, animals received daily subcutaneous AOD-9604 at literature-reported research doses of 250 mcg/kg for 12 weeks alongside continued high-fat diet feeding. 7

The primary endpoint was total body fat mass assessed by dual-energy X-ray absorptiometry (DEXA). Treated animals showed statistically significant reductions in total fat mass of approximately 30-50% compared to vehicle controls over the study period, with no significant change in lean body mass. Feed intake was not significantly altered, suggesting the fat-mass changes resulted from altered energy expenditure and fat mobilization rather than suppression of appetite, a finding that aligns with the absence of central nervous system receptor targets for AOD-9604.

The ob/ob mouse data were broadly consistent: AOD-9604 treatment reduced abdominal fat depot weights at necropsy, with epididymal and perirenal fat pads showing the greatest proportional reductions. Histological examination of adipose tissue showed smaller mean adipocyte cross-sectional area, consistent with enhanced lipid mobilization. 4

A key limitation is the genetic heterogeneity of the ob/ob model relative to human polygenic obesity. The ob/ob mouse lacks leptin, creating a very specific hormonal context that is not representative of most human obesity phenotypes. Results in these animals often overestimate efficacy in human translation.

Study 3, Human Phase IIb Trial by Metabolic Pharmaceuticals

The human clinical data for AOD-9604 are more extensive than for the vast majority of research peptides. Metabolic Pharmaceuticals Ltd completed a multicenter, double-blind, randomized, placebo-controlled Phase IIb trial enrolling obese adults (BMI 30-40 kg/m²) randomized to oral AOD-9604 at doses of 1 mg, 2 mg, or 3 mg per day versus placebo for 12 weeks. 1

The primary endpoint was change in body weight from baseline. The trial reported modest but numerically positive weight reductions in all treatment arms compared to placebo, with the 1 mg/day arm showing a mean weight loss advantage of approximately 1.5-2.5 kg over placebo at 12 weeks in the intent-to-treat analysis. However, the differences did not reach the pre-specified threshold for statistical significance across the study population as a whole.

Post-hoc subgroup analyses suggested that participants with higher baseline fasting insulin levels may have responded more robustly, raising the hypothesis that insulin resistance status modulates the efficacy of AOD-9604's ADRB3-dependent pathway. This remains a hypothesis requiring prospective validation. The safety profile was favorable: no clinically significant changes were observed in fasting glucose, insulin, IGF-1, HbA1c, lipid panels, liver function tests, or cardiovascular parameters. No serious adverse events were attributed to the study drug. 1

The trial's limitation was that oral bioavailability of peptides is notoriously variable and generally low unless specific oral delivery technologies are employed. The subcutaneous route used in animal studies likely achieves considerably higher bioavailability than the oral route studied in the trial, and it is possible that dose selection for the human trial was subtherapeutic relative to the effective range based on preclinical weight-adjusted dosing.

Study 4, AOD-9604 in Cartilage and Bone Research

A distinct literature has developed examining AOD-9604 in the context of musculoskeletal repair. A series of in vitro studies using human chondrocytes and ex vivo cartilage explants treated with pro-inflammatory cytokines (TNF-alpha, IL-1beta) to simulate osteoarthritis conditions reported that AOD-9604 treatment reduced the expression of matrix metalloproteinases (MMP-3, MMP-13) and increased the synthesis of aggrecan and collagen type II, which are the principal structural proteoglycans of articular cartilage. 10

An in vivo rodent study using the surgically induced destabilization of the medial meniscus (DMM) model of osteoarthritis administered intra-articular AOD-9604 alone and in combination with sodium hyaluronate. Animals receiving the combination showed the greatest preservation of cartilage thickness, assessed by Safranin-O staining and OARSI scoring at 8 weeks post-surgery, compared to vehicle and single-agent controls. 11

The mechanistic explanation proposed by this group involves TGF-beta pathway activation in chondrocytes, with AOD-9604 potentially acting as a partial agonist at a TGF-beta surface receptor or co-receptor. This mechanistic hypothesis is supported only by correlative gene expression data and has not been confirmed by receptor binding studies or pathway inhibitor experiments in the AOD-9604 context. The sample sizes in the DMM model study were modest (n=8 per group), which limits statistical power and increases the risk of type I error in the subgroup analyses.

These musculoskeletal findings are scientifically interesting but represent a relatively early stage of investigation compared to the adipose-tissue literature. Researchers designing studies in this area should treat the existing cartilage data as hypothesis-generating rather than hypothesis-confirming.

Study 5, Doping Detection and Analytical Chemistry Research

Because AOD-9604 was listed on the World Anti-Doping Agency (WADA) prohibited list as part of the category of GH-related peptides, a substantial body of analytical chemistry research has developed around its detection in biological fluids. Mass spectrometry-based detection methods have been validated for urine and blood matrices, with several groups reporting successful identification of AOD-9604 and its metabolites at picogram-per-milliliter concentrations using LC-MS/MS and HRMS approaches. 12

One 2015 study published in Drug Testing and Analysis characterized the urinary metabolite profile following a single administration of AOD-9604 in research-eligible study participants. The parent compound and two major metabolites were identified, with the parent compound detectable for approximately 24-48 hours post-administration and metabolites detectable for up to 72 hours, depending on dose and individual variation. 13

From a basic research perspective, these doping-detection studies are valuable because they provide authenticated reference data on the pharmacokinetic behavior of the compound in a controlled human setting, complementing the clinical trial data. The metabolite identification work also informs researchers about the primary biotransformation pathways, which appear to involve N-terminal and central-sequence proteolytic cleavage rather than side-chain modification.

Pharmacokinetics

Absorption and Distribution

Following subcutaneous administration in rodent pharmacokinetic studies using ¹²⁵I-labeled AOD-9604, radioactivity was detected in adipose depots within 15-30 minutes, consistent with rapid absorption from the subcutaneous space and preferential distribution to tissues bearing the relevant receptors. 6 Whole-body autoradiography images showed concentration in abdominal and inguinal fat pads, with lower but detectable signal in liver and kidney, which are likely involved in peptide clearance rather than pharmacodynamic action.

The volume of distribution (Vd) data suggest the compound leaves the central plasma compartment relatively quickly after administration and concentrates in peripheral tissues. This is the typical behavior of small peptides that interact with cell-surface receptors in peripheral organs. The rapid tissue uptake means that plasma half-life measurements, while short at approximately 30-45 minutes for the parent compound, underestimate the duration of receptor occupancy and downstream signaling at the target tissue level.

Metabolism and Elimination

Like all peptides, AOD-9604 is subject to proteolytic degradation. The primary enzymes responsible are serine proteases and dipeptidyl peptidases in plasma and tissue compartments, with the disulfide loop region offering partial structural protection against rapid N-terminal exopeptidase activity. 13 The primary fragments identified in urine following administration correspond to N-terminal cleavage products retaining the C-terminal disulfide loop, and smaller fragments lacking the loop arising from central proteolysis.

Renal filtration of intact peptide is limited by the approximately 30-minute plasma half-life, but proteolytic fragments below the glomerular filtration threshold (roughly below 10 kDa, which all AOD-9604 fragments satisfy) are excreted renally, explaining the urinary detectability window of 24-72 hours. 12

Purity and Verification

What a CoA Should Contain

A certificate of analysis (CoA) for a research-grade AOD-9604 vial should contain the following minimum information: HPLC purity trace with integration confirming the main peak area percentage, mass spectrometry data (preferably HRMS) confirming the correct molecular ion [M+H]+ at approximately 1816.1 Da for the protonated form, and a statement of testing method and reference standards used. A vial described as "≥98% purity by HPLC" without MS confirmation leaves open the possibility that the remaining co-eluting material is the inactive scrambled-disulfide isomer, which would not be resolved from the correct form by standard reversed-phase HPLC.

WADA anti-doping laboratories have published detailed LC-HRMS methods for confirming AOD-9604 identity and quantifying the compound in biological matrices. 12 While research labs are not typically equipped with anti-doping-grade HRMS, the published analytical chemistry literature provides validated reference methods against which vendor CoA data can be evaluated. Vendors who commission their testing at ISO 17025-accredited contract laboratories and provide the raw spectral data alongside the summary CoA are offering a meaningfully higher standard of quality assurance.

Independent Verification Approaches

Researchers who need to verify AOD-9604 identity independently can use several approaches. Electrospray ionization mass spectrometry (ESI-MS) on a benchtop single-quadrupole instrument can confirm the correct monoisotopic mass within acceptable error bounds. More precise confirmation requires a high-resolution instrument (Orbitrap or Q-TOF) capable of resolving the disulfide-containing form from a reduced form that differs by only 2 Da (the mass of two hydrogen atoms). 9

NMR characterization of the disulfide bond configuration is technically possible but impractical for routine quality control given the cost and time involved. The practical standard for a research lab is ESI-MS confirmation of correct molecular weight plus HPLC purity. For researchers working in fields where compound identity is publication-critical, submitting an aliquot to a commercial peptide characterization service before beginning biological experiments is prudent.

For guidance on evaluating supplier CoA documentation, reading HPLC traces, and identifying red flags in vendor documentation, see our supplier evaluation guide.

Dosage and Reconstitution

Literature-Reported Research Doses

Preclinical rodent studies have employed a range of AOD-9604 doses depending on route of administration and experimental objectives. Subcutaneous protocols in DIO mice typically used 250-500 mcg/kg per day, administered once daily, over study periods of 4-12 weeks. 7 The ob/ob mouse studies used comparable dose ranges. Converting from mouse to larger species using standard body surface area allometric scaling (a well-established but imperfect method in pharmacology) yields substantially lower weight-adjusted doses for larger organisms, but these conversions should be performed carefully and are discussed in detail in our dosage calculation guide.

The human clinical trials employed oral doses of 1-9 mg per day in Phase I safety studies and 1-3 mg per day in the Phase IIb efficacy trial. 1 These oral doses are not directly translatable to subcutaneous research protocols given the route-of-administration differences in bioavailability. No published study provides a validated subcutaneous-to-oral dose conversion ratio for AOD-9604 specifically.

For in vitro cell culture experiments, the literature-reported concentrations used in adipocyte studies range from 1 nM to 1 microM, with most studies reporting significant effects in the 10-100 nM range. 8

Reconstitution Protocol for a 5 mg Vial

The 5 mg vial contains approximately 2,756 nmol of AOD-9604 (based on the 1815.1 Da molecular weight). For in vitro work requiring micromolar-range concentrations, the following worked examples illustrate standard dilution approaches.

Example 1, Stock solution at 1 mg/mL: Add 5.0 mL of sterile bacteriostatic water to the lyophilized pellet. This yields 5 mL of solution at 1 mg/mL (approximately 551 nmol/mL or 551 microM). This concentration is suitable as a stock for dilution to working concentrations in cell culture media.

Example 2, Stock solution at 0.5 mg/mL for lower-concentration work: Add 10.0 mL of bacteriostatic water to the 5 mg pellet. This yields 10 mL at 0.5 mg/mL (approximately 275 nmol/mL). For experiments requiring 100 nM working concentration in a cell culture well, dilute 1 part stock to 2,750 parts culture medium.

Example 3, Working concentration for rodent in vivo studies at 250 mcg/kg in a 25 g mouse: A 25 g mouse requires 6.25 mcg per injection (0.00625 mg). Using a 0.1 mL injection volume (typical for SC dosing), the required concentration in the injection solution is 0.0625 mg/mL. Reconstitute the vial at 1 mg/mL and dilute 1:16 with sterile saline before loading into the injection syringe.

For detailed reconstitution technique including aseptic practice, vial preparation, and handling of lyophilized peptide cakes, see our comprehensive peptide reconstitution guide.

Storage After Reconstitution

Reconstituted AOD-9604 solutions should be aliquoted immediately after preparation to minimize freeze-thaw cycles, which can accelerate disulfide bond scrambling and peptide aggregation. Individual aliquots stored at -80°C in low-protein-binding microcentrifuge tubes maintain activity for at least 6 months based on general peptide stability principles; AOD-9604-specific stability data at -80°C beyond this range have not been published. Avoid storage in glass vials with natural rubber stoppers, which can introduce leachates at long storage times.

Side Effects and Safety

Human Clinical Trial Safety Data

The most systematic human safety data comes from the Phase I and Phase IIb trials conducted by Metabolic Pharmaceuticals. Phase I studies evaluated single and multiple oral doses from 0.25 mg to 9 mg per day in healthy volunteers. No dose-limiting toxicities were identified. The most commonly reported adverse events were mild gastrointestinal symptoms (nausea, loose stools) at the highest doses, which were transient and resolved without intervention. 1

Critically, the trials measured a comprehensive endocrine panel including serum IGF-1, fasting insulin, fasting glucose, HbA1c, and thyroid function. None of these markers showed clinically significant changes compared to placebo, consistent with the preclinical mechanistic data showing absence of GH receptor activation and IGF-1 induction. 1 This endocrine-safety profile is a notable distinction from rhGH administration, which reliably elevates IGF-1 and can induce insulin resistance at pharmacological doses.

Preclinical Safety Signals

In rodent chronic dosing studies, AOD-9604 was not associated with changes in organ weights, hematological parameters, or histopathological findings on tissue examination at literature-reported research doses. 4 No carcinogenicity studies have been published for AOD-9604 specifically, though the absence of IGF-1 elevation is considered a favorable indicator from a proliferation-risk perspective, given the well-established role of IGF-1 signaling in promoting cell proliferation.

No published teratogenicity or reproductive toxicology studies were identified in the literature search for this review. This is a data gap that should be noted when designing research protocols involving pregnant or reproductively active animals.

Considerations for Injection Site Reactions

In research settings employing subcutaneous administration in rodents, no systematic injection site pathology has been reported at literature-reported research doses in the published literature. For any peptide administered subcutaneously, standard precautions include rotating injection sites, using appropriate needle gauge and injection technique, and monitoring for local tissue reaction. The peptide reconstitution guide covers injection preparation in detail.

Immunogenicity

Peptide fragments of endogenous human proteins can in principle elicit anti-drug antibodies, particularly with repeated administration. No immunogenicity data specific to AOD-9604 were identified in the published preclinical literature. The human clinical trial did not report immune-mediated adverse events. Given that the peptide sequence is derived from a self-protein (hGH), immunogenicity risk is expected to be relatively low compared to fully foreign peptides, but this has not been systematically studied with the standard battery of immunogenicity assays. Researchers designing repeated-dose animal studies should consider including anti-drug antibody assessments as an exploratory endpoint.

How It Compares

AOD-9604 vs CJC-1295 and Ipamorelin

CJC-1295 and Ipamorelin are both GH secretagogues that work upstream of AOD-9604 in the GH axis by stimulating pulsatile GH release from the pituitary. Their metabolic effects, including fat-mass changes, are largely mediated through the downstream consequences of elevated GH and subsequently elevated IGF-1. 14 AOD-9604, by contrast, bypasses the pituitary entirely and acts directly on adipose tissue. This mechanistic distinction has several research implications: AOD-9604 studies allow isolation of direct adipose effects from the systemic anabolic milieu created by elevated GH/IGF-1 combinations.

For researchers interested specifically in the adipose tissue lipolysis pathway independent of anabolic context, AOD-9604 offers a cleaner pharmacological tool. For researchers interested in the full pleiotropic effects of GH axis stimulation, secretagogues like Ipamorelin are more appropriate.

AOD-9604 vs Tesamorelin

Tesamorelin is a stabilized GHRH analog that received FDA approval for HIV-associated lipodystrophy, a condition characterized by visceral fat accumulation in patients on antiretroviral therapy. 15 Its mechanism involves pituitary GH stimulation, with the resulting GH pulses driving visceral fat mobilization through hepatic IGF-1 and direct adipose GH receptor signaling. The clinical efficacy data for tesamorelin in its approved indication are substantially more robust than the clinical data for AOD-9604 in general obesity.

AOD-9604 differs by avoiding pituitary involvement entirely and not elevating IGF-1, which makes it a distinct molecular probe for mechanistic research. The two compounds are not directly substitutable as research tools because they engage different parts of the GH axis biology.

Where to Buy

Apollo Peptide Sciences lists AOD-9604 as a 5 mg lyophilized vial at $60.00 per unit. The internal product review page at /product/aod-9604-peptide-2 contains the most current information on availability, lot-specific CoA data, and independent verification reports where available.

Before ordering any research peptide, researchers should review our supplier evaluation framework, which covers the criteria we apply when assessing vendor quality assurance practices, including CoA documentation standards, third-party testing policies, shipping and cold-chain protocols, and regulatory compliance posture. Our disclosure page explains how affiliate relationships are structured on this site: product links on internal review pages direct to affiliate URLs, but editorial recommendations are made independently of affiliate compensation. Our disclaimer sets out the full legal and regulatory framework governing the research-only use of compounds reviewed on this site.

Open Research Questions

Several mechanistic and translational questions about AOD-9604 remain unresolved in the published literature. Documenting them is relevant both for researchers designing new studies and for placing the existing evidence in appropriate context.

Receptor binding structure: The precise molecular interaction between AOD-9604 and ADRB3 has not been resolved crystallographically or by cryo-EM. While pharmacological evidence for ADRB3 involvement is strong, alternative or additional receptor interactions (for example, with beta-1/2 subtypes at high concentrations, or with as-yet-unidentified binding partners in chondrocytes) have not been ruled out. 2

Oral bioavailability determinants: The oral Phase IIb trial used a proprietary formulation, the details of which are not fully disclosed in the public literature. Whether the apparent lack of efficacy reflects insufficient bioavailability, incorrect dose range, population heterogeneity, or a genuine limit of the pharmacodynamic mechanism in the context of human polygenic obesity cannot be determined from the published data alone. A study directly comparing subcutaneous and oral bioavailability in humans using identical doses has not been published.

Sex and hormonal context: Preclinical rodent studies were predominantly conducted in male animals. ADRB3 expression and adipocyte physiology differ between male and female animals and vary with gonadal hormone status. Whether sex modulates AOD-9604 efficacy in a clinically meaningful way is not established.

Cartilage mechanism: The emerging data on chondroprotective effects are scientifically interesting but rest on a thin experimental base. The proposed TGF-beta pathway involvement has not been confirmed by direct binding assays. Replication by independent groups in well-powered studies is needed before these findings can be treated as established. 10

Long-term in vivo safety: The longest published rodent study was 12 weeks. Long-term (greater than 6 months) safety data in any species have not been published.

FAQ

References